Hi,

Take a look at this…

It’s smaller than a fingertip…

It’s made of glass…

And it’s about to unlock the next wave of AI growth.

Jensen Huang, Nvidia's CEO, says this “light-speed” device is shattering the limitations of AI… and without it, AI can’t scale.

Google Ventures says it’s the future of AI compute...

And Sequoia Capital — the firm that backed Anthropic and OpenAI — calls it a “holy grail.”

Already, Elon Musk, Mark Zuckerberg, Cathie Wood, and Bill Gates are moving money to prepare for what’s coming…

Yet most Americans have never heard of it.

Wall Street insider Jason Bodner — the same man who called Nvidia at $4.50 — says this device is about to launch a whole new wave of AI winners…

And to prove it, he’s giving away his #1 stock involved with it — for free.

Click here to learn more. (No purchase necessary.)

We have so much to look forward to,

Jeff Brown
Founder & CEO, Brownstone Research

P.S. Stocks tied to this “light-speed” device already surged 133%, 217%, and even 320% — in a few short months. But it’s just getting started. Click here before the mainstream catches on.

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

Written by Jeffrey Neal Johnson. Originally Published: 7/13/2026.

When a late-stage clinical trial misses its primary endpoint, the market reaction rarely distributes evenly across the sector. The fallout often reveals fundamental truths about single-asset exposure, pipeline diversification and the competitive moats protecting established treatments. The July 9 announcement from AstraZeneca (NYSE: AZN) and Ionis Pharmaceuticals (NASDAQ: IONS) regarding the CARDIO-TTRansform Phase 3 trial provides a real-time master class in these market dynamics.

The investigational use of Wainua, also known as eplontersen, failed to achieve statistical significance on its primary composite endpoint of cardiovascular mortality and recurrent cardiovascular events after 140 weeks. The treatment targets transthyretin-mediated amyloid cardiomyopathy, a fatal disease that causes misfolded proteins to accumulate in the heart muscle.

The clinical failure removes an anticipated competitor from a highly lucrative market and triggers an immediate rotation of capital across the broader biotech sector.

Unmasking the Trial: Stabilizers Block the Path

To understand why the market repriced these assets so aggressively, investors must look beneath the headline failure and evaluate the underlying subgroup data. The treatment landscape relies heavily on stabilizer medications such as Vyndamax, manufactured by Pfizer (NYSE: PFE). In the CARDIO-TTRansform trial, patients already taking these baseline stabilizers accounted for 57% of the study population at the start of the program, and that proportion rose to roughly 80% by the end of the study.

Wainua failed to demonstrate an additive treatment effect in this stabilizer subgroup. The drug did not improve outcomes for patients already receiving standard-of-care treatment.

In the monotherapy subgroup, which included patients not taking any stabilizers, Wainua demonstrated a hazard ratio of 0.71, translating to a 29% risk reduction. While that figure aligns closely with competitor benchmarks, it offers limited commercial utility. A pharmaceutical product cannot capture meaningful market share if it works only for the rapidly shrinking fraction of patients who are completely naive to standard-of-care treatments.

This data exposes a fundamental disparity between antisense oligonucleotides such as Wainua and the RNA interference therapies developed by competitors. Alnylam Pharmaceuticals (NASDAQ: ALNY) previously validated its competing RNA interference therapy, Amvuttra, in both the monotherapy and stabilizer-combination subgroups of its HELIOS-B trial. By failing to show that essential additive benefit, Wainua is effectively locked out of the most lucrative and pretreated segment of the total addressable market.

Asymmetric Damage: Single-Asset Squeeze

The financial damage stemming from this clinical miss was distributed unevenly, highlighting the stark contrast between concentrated pipeline risk and structural business diversification.

Ionis Pharmaceuticals absorbed the brunt of the impact. Shares fell by more than 9% in a single day, pushing the stock down more than 26% since the start of the year and reducing its total market capitalization to $9.63 billion.

Ionis Pharmaceuticals faces acute vulnerability because it was relying on Wainua to expand its addressable market. The current regulatory approval for ATTR polyneuropathy covers fewer than 50,000 patients globally.

The cardiomyopathy indication would have unlocked a total addressable market of 300,000 to 500,000 patients.

Without that expansion, Ionis Pharmaceuticals faces a difficult fundamental reality. The developer currently generates negative earnings, with an earnings-per-share loss of 56 cents. First-quarter 2026 revenue surged to $246 million, an 87% increase year over year, but rapid commercial infrastructure expansion kept profit margins compressed, resulting in a net loss of $93 million.

Although the company's trailing return on equity remained deeply negative at -58.65%, its balance sheet risk softened substantially after Ionis eliminated $633 million in convertible debt using restricted escrow cash on April 1, 2026.

AstraZeneca tells a completely different fundamental story. AstraZeneca's stock price fell briefly intraday before institutional buyers stepped in to support it. A $266.54 billion pharmaceutical sector giant does not live or die by a single indication expansion.

AstraZeneca generates $60.44 billion in annual sales, supported by blockbuster oncology franchises such as Tagrisso and Imfinzi. The company operates with a healthy 17.19% net margin, a robust 30.86% return on equity and a conservative debt-to-equity ratio of 0.52.

Pretrial models projected that Wainua could reach peak sales of up to $6.5 billion with approval for ATTR-CM.

Analysts have since revised those estimates down to approximately $4 billion. Erasing a $2.5 billion premium certainly adjusts near-term valuation models, but it barely registers against AstraZeneca's stated $80 billion top-line revenue target for 2030. The institutional market accurately perceived the drop as a temporary mispricing rather than a structural downgrade.

The Vultures Circle: Rivals Catch the Tailwinds

Markets dislike a vacuum. When Wainua was removed as an imminent competitive threat, capital immediately rotated into rival drugmakers positioned to capture the newly unaddressed market share. The trial failure preserves the existing market structure and the pricing power of the leading therapies in the disease space.

BridgeBio (NASDAQ: BBIO) emerged as the most direct beneficiary, with shares up 16% to touch new 52-week highs following the initial announcement. BridgeBio is actively launching its newly approved therapy, Attruby.

Without Wainua entering the market to compress margins and force aggressive discounting, BridgeBio enjoys a substantially clearer commercial runway. BridgeBio recently secured a $1 billion Series A convertible preferred equity raise led by Sixth Street and KKR. This infusion provides a substantial capital buffer to execute an aggressive commercial launch, funding sales-force deployment without immediate dilution concerns.

Pfizer and Alnylam Pharmaceuticals also experienced immediate bid support. Pfizer maintains its multibillion-dollar stronghold with Vyndamax, knowing that physicians will not have to consider transitioning stable patients to a competing therapy. Alnylam Pharmaceuticals sustains its clinical momentum, as its RNA interference mechanism remains the only proven combination therapy that effectively builds on existing stabilizers.

Discharging the Risk: Portfolio Lessons Learned

The failure of the CARDIO-TTRansform trial fundamentally rewrites the competitive map for amyloidosis treatments. It draws a hard line between therapies that can improve the standard of care and those that merely match it in isolation.

For the companies involved, the data reinforces the protective power of a diversified revenue base. AstraZeneca can easily absorb the setback through its oncology and metabolic divisions, while Ionis Pharmaceuticals faces prolonged fundamental pressure as it navigates profitability challenges and stalled growth drivers. Investors evaluating biotech allocations might consider prioritizing developers with validated combination therapies or deeply diversified pipelines to mitigate these specific clinical risks.

Dear Reader,

The IMF doesn't issue warnings like this often, but when they do... you need to listen.

For your entire life, debt crises have always happened anywhere but America.

Italy in the 90s. Argentina in 2001. Greece in 2009.

America was always safe…

But now the IMF is projecting that by 2031, US debt will climb to 140% of GDP.

That's higher than Greece's debt was when their entire economy collapsed.

And when their system broke, it was chaos.

Retirees' pensions got slashed 40% overnight. People who saved for 40 years, who followed all the rules, watched their retirement go up in smoke.

It only took 24 months.

Now imagine that coming to America.

When Greece broke, the EU swooped in with $300 billion in emergency bailouts. Greece was fine.

But when America crosses that line? There's no one bigger to save us. We ARE the emergency bailout for the rest of the world.

And we're following Greece's exact playbook right now.

I'm Tan Gera, ex-Wall Street investment banker and CFA© Charterholder.

I walked away because I saw how the system really works. Banks protect themselves first. Politicians kick the can. And regular folks like you are left holding the bag.

That's why my team now teaches over 4,500 members to build what we call a "financial firewall"... a parallel savings system that operates completely outside the Federal Reserve's control.

You can't fix $38 trillion in debt. You can't stop Congress from spending.

But you CAN control how much of your wealth stays exposed to the fallout.

Click here to learn how to build your financial firewall before 2030 →

The IMF projects 140% debt-to-GDP by 2031. That's less than 60 months away.

To your sovereignty,
Tan Gera, CFA©
Decentralized Masters

P.S. When Greece hit 130% debt-to-GDP, pensions were slashed 40% overnight. America is projected to hit 140% by 2031. Watch how to protect your retirement before we cross that line →

Defense Earnings Show Readiness Now and Modernization Ahead

Written by Chris Markoch. Published: 7/25/2026.

Several of the nation's top defense contractors reported earnings against a backdrop of the U.S. conflict with Iran, which appears to be entering a new phase. Meanwhile, on Capitol Hill, lawmakers are trying to secure funding to address the military's immediate needs while still grappling with the Trump administration’s longer-term goal of modernizing the military.

This gives investors two stories to consider. Lockheed Martin (NYSE: LMT), Northrop Grumman (NYSE: NOC), and RTX Corporation (NYSE: RTX) all posted strong quarters this week. But the numbers tell only half of the story.

One story focuses on readiness right now, as the Strait of Hormuz remains a flashpoint and U.S. forces remain engaged with Iran. The other is about modernization: the decade-long buildout of next-generation aircraft, interceptors, and autonomous systems.

Investors watching this earnings season need to weigh both. A company can look strong on paper while still being weighted toward one side of the story. Here's why investors can trust these three defense contractors in either scenario.

Lockheed, Northrop, and RTX Build Record Backlogs After Earnings

All three contractors delivered the kind of quarter that makes a bull case easy to write. Lockheed Martin posted $20.1 billion in sales and $7.94 in earnings per share (EPS). Its book-to-bill ratio hit 3.2x, indicating that new orders outpaced shipments by more than three to one. Backlog reached $230 billion, and management raised full-year sales guidance to $79.75–$81.75 billion.

Northrop Grumman leaned even more heavily on its backlog story. The company reported a record $105 billion backlog, up 17% year over year, alongside $10.9 billion in quarterly sales. Reported EPS fell 6% to $7.68, but that decline was purely an accounting artifact tied to last year's gain from the Training Services divestiture. Adjusted earnings guidance still moved higher.

RTX stole the show on growth. Adjusted sales climbed 16% organically to $24.7 billion, adjusted EPS jumped 21% to $1.89, and backlog surged 22% to $289 billion. The standout figure was $43 billion in new awards this quarter, nearly $20 billion of it at the Raytheon segment alone.

Missile Defense Demand Supports Near-Term Growth for Defense Stocks

The Strait of Hormuz has been an active flashpoint since February, and the recent collapse of the U.S.-Iran ceasefire has renewed pressure on missile defense and munitions. Not every defense stock is equally exposed to that story, and the differences matter for near-term revenue.

Lockheed Martin and Northrop Grumman form the backbone of the missile defense supply chain. Lockheed's Missiles and Fire Control segment grew sales 19%, driven by PAC-3 and THAAD volume. Northrop manufactures THAAD interceptor rounds and posted a record $35 billion Defense Systems backlog tied to Sentinel and missile defense demand.

RTX carries the munition-replenishment story through its Raytheon segment. The company disclosed more than $5 billion in new contracts for GEM-T effectors, the upgraded Patriot interceptor, headed to Ukraine, Poland, and the U.S. government. Raytheon's book-to-bill ratio hit 2.42, signaling that demand is outpacing even expanded production capacity.

Both RTX and Northrop flagged capacity expansion this quarter. That's a signal that demand, rather than contracts, is now the binding constraint on how quickly these companies can respond to a live conflict.

Military Modernization Creates Long-Term Growth Opportunities

Beyond the current crisis sits a slower-moving story: the multiyear modernization of the U.S. military. This is where each company's flagship programs diverge the most and where longer-term investors should focus.

Northrop's marquee program is the B-21 Raider, the next-generation stealth bomber. Management specifically cited an agreement to accelerate B-21 production capacity as a long-term value driver, positioning the company for a deterrence mission built for the 2030s and beyond.

Lockheed straddles both timelines. Its F-35 program continues to ramp, although some of this quarter's gain reflects the absence of prior-year losses rather than new demand. More telling is the growth in the Next Generation Interceptor, the homeland missile shield meant to succeed today's PAC-3 and THAAD systems.

RTX's modernization bet centers on autonomy. Collins Aerospace's Sidekick software was down-selected for the Air Force's Collaborative Combat Aircraft program, the drone-wingman concept shaping future air combat. Pratt & Whitney also secured certification for its GTF Advantage engine this quarter.

What Defense Investors Should Watch After Earnings

The clearest signal from this earnings season is that backlog composition matters more than backlog size. A backlog full of interceptors and munitions reflects exposure to what's happening in the Gulf today. A backlog full of next-generation platforms reflects exposure to a modernization cycle that is still years from peaking.

What's notable is that all three companies are growing on both fronts simultaneously. That dual exposure, rather than a bet on one story over the other, is likely why Lockheed, Northrop, and RTX all raised guidance in the same week.